Zobrazeno 1 - 3
of 3
pro vyhledávání: '"S M Nasifuzzaman"'
Autor:
Puri, Kavya Sri Racherla, Katrina Dovalovsky, Meet Patel, Emma Harper, Jacob Barnard, S M Nasifuzzaman, Mason Smith, Riya Sikand, Eva Drinka, Neelu
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3461
Osimertinib, an irreversible tyrosine kinase inhibitor, is a first-line therapy in EGFR-mutant NSCLC patients. Prolonged treatment with Osimertinib leads to resistance due to an acquired C797S mutation in the EGFR domain and other mechanisms, such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::a06db21abbb0b94989226ea0b3f9a7e2
Publikováno v:
Cancer Research. 83:428-428
Background: Tyrosine Kinase Inhibitors (TKIs) such as Erlotinib (ER) and Osimertinib (OR) are being used to treat lung cancer patients with EGFR mutations; however, patients develop resistance to these drugs within 10-18 months. EGFR-TKI resistance m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c19e57701dd49e1541ae259be73e99a
https://doi.org/10.1158/1538-7445.am2023-428
https://doi.org/10.1158/1538-7445.am2023-428
Autor:
Taylor Rager, Adam Eckburg, Meet Patel, Rong Qiu, Shahina Gantiwala, Katrina Dovalovsky, Kelly Fan, Katie Lam, Claire Roesler, Aayush Rastogi, Shruti Gautam, Namrata Dube, Bridget Morgan, S M Nasifuzzaman, Dhruv Ramaswami, Varun Gnanasekar, Jeffrey Smith, Aftab Merchant, Neelu Puri
Publikováno v:
Cancers. 14:3779
Melanoma possesses invasive metastatic growth patterns and is one of the most aggressive types of skin cancer. In 2021, it is estimated that 7180 deaths were attributed to melanoma in the United States alone. Once melanoma metastasizes, traditional t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c44eec643891b4e0fa657d02ead0daa1
https://doi.org/10.3390/cancers14153779
https://doi.org/10.3390/cancers14153779